BioWorld MedTech

July 6, 2017

Edwards wins FDA approval for resilient heart valve device

Edwards Lifesciences Corp. received FDA approval for its Inspiris Resilia aortic valve. The Irvine, Calif.-based company said the valve is resistant to calcification, and leads the way for a new class of resilient heart valve devices. Read More

Fingerstick-free, disposable CGMs (and more) are on the way, but when?

NICE sees economics of Abbott's Freestyle Libre CGM as 'uncertain'

U.K. industry leaders encouraged by ministers' stance on post-Brexit drug/device regulation

U.S. stent makers view India price caps with suspicion

Other news to note

Financings

Daily M&A

Product briefs

Regulatory front

BioWorld MedTech's Oncology Extra

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...